Distant metastasis prediction via a multi-feature fusion model in breast cancer

Abstract

This study aimed to develop a model that fused multiple features (multi-feature fusion model) for predicting metachronous distant metastasis (DM) in breast cancer (BC) based on clinicopathological characteristics and magnetic resonance imaging (MRI). A nomogram based on clinicopathological features (clinicopathological-feature model) and a nomogram based on the multi-feature fusion model were constructed based on BC patients with DM (n=67) and matched patients (n=134) without DM. DM was diagnosed on average (17.31±13.12) months after diagnosis. The clinicopathological-feature model included seven features: reproductive history, lymph node metastasis, estrogen receptor status, progesterone receptor status, CA153, CEA, and endocrine therapy. The multi-feature fusion model included the same features and an additional three MRI features (multiple masses, fat-saturated T2WI signal, and mass size). The multi-feature fusion model was relatively better at predicting DM. The sensitivity, specificity, diagnostic accuracy and AUC of the multi-feature fusion model were 0.746 (95% CI: 0.623-0.841), 0.806 (0.727-0.867), 0.786 (0.723-0.841), and 0.854 (0.798-0.911), respectively. Both internal and external validations suggested good generalizability of the multi-feature fusion model to the clinic. The incorporation of MRI factors significantly improved the specificity and sensitivity of the nomogram. The constructed multi-feature fusion nomogram may guide DM screening and the implementation of prophylactic treatment for BC.

MR Imaging Phenotypes and Features Associated with Pathogenic Mutation to Predict Recurrence or Metastasis in Breast Cancer

“…Wang et al [18] found that the rate of disease-free survival at 5 years was 73.3% among BRCA mutation carriers, as compared with 91.1% among non-carriers. Previous studies demonstrated that some factors including tumour size, multiple masses, fat-saturated T 2 WI signal, were con rmed to be associated with distant metastasis [25][26] . Some independent clinicopathologic factors were previously con rmed to be associated with distant metastasis.…”

Survival Estimation, Prognostic Factors Evaluation, and Prognostic Prediction Nomogram Construction of Breast Cancer Patients with Bone Metastasis in the Department of Bone and Soft Tissue Tumor: A Single Center Experience of 8 Years in Tianjin, China

“…In recent years, the definition of BM (SBM/MBM) was a global concern in distant metastasis [ 26 , 27 ]. Sufficient evidence showed the significant difference between SBM and MBM in clinicopathologic characteristics and survival outcome [ 21 , 26 , 28 ]. However, SBM and MBM were still not well defined, which might be the main reason for inconsistent conclusions in previous studies [ 26 , 27 ].…”

Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer

“…Cancer antigen 15-3 (CA15-3) in addition to carcinoembryonic antigen (CEA) along with cancer antigen 125 (CA125) are extensively used in the clinical practice of breast cancer as serum tumor markers. These have been developed as noninvasive, easily available, and cost-effective tumor markers for immediate diagnosis, monitoring, and prediction of breast cancer [ 5 – 7 ].…”